Menu

Markets

Research

News

Learn

AI Chat
Get the app WatchlistsPortfoliosAlerts
Sign in

Clovis Oncology, Inc. CLVS

Full chart Compare
Set alert

Price alert · CLVS

All alert types
0.08 +0.08

Day range unavailable

52-week range unavailable

Discussion (3636)

Sign in to join the discussion

Febreary,21. 2019 CLVS 6 years ago #3561

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
OMB APPROVAL

OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
 Â

  1. Name and Address of Reporting Person*
    IVERS-READ GILLIAN C

(Last)
(First)
(Middle)
C/O CLOVIS ONCOLOGY, INC.
5500 FLATIRON PARKWAY, SUITE 100

(Street)
BOULDER
CO
80301 2. Issuer Name and Ticker or Trading Symbol
Clovis Oncology, Inc. [ CLVS ] 5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
3. Date of Earliest Transaction (Month/Day/Year)
01/31/2020
4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line)
IVERS-READ GILLIAN C
(Last) (First) (Middle)
C/O CLOVIS ONCOLOGY, INC.
5500 FLATIRON PARKWAY, SUITE 100
BOULDER CO 80301
(City) (State) (Zip)
Director 10% Owner
X Officer (give title below) Other (specify below)
See Remarks
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

  1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price


Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

  1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares


Restricted Stock Units (1) 01/31/2020 A 74,000 (2) (2) Common Stock 74,000 $0.00 74,000 D
Explanation of Responses:

  1. Each Restricted Stock Unit represents the right to receive one share of Common Stock.
  2. The Restricted Stock Units shall vest as to 25% of the units on February 1, 2021, and the remainder shall vest in substantially equal installments over the 12 quarters immediately following such date.
    Remarks:
    Executive Vice President of Technical Operations and Chief Regulatory Officer
    s/ Gillian C. Ivers-Read 01/31/2020
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

  • If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Febreary,21. 2019 CLVS 6 years ago #3562

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
OMB APPROVAL

OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
 Â

  1. Name and Address of Reporting Person*
    Rolfe Lindsey

(Last)
(First)
(Middle)
C/O CLOVIS ONCOLOGY, INC.
5500 FLATIRON PARKWAY, SUITE 100

(Street)
BOULDER
CO
80301 2. Issuer Name and Ticker or Trading Symbol
Clovis Oncology, Inc. [ CLVS ] 5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
3. Date of Earliest Transaction (Month/Day/Year)
01/31/2020
4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line)
Rolfe Lindsey
(Last) (First) (Middle)
C/O CLOVIS ONCOLOGY, INC.
5500 FLATIRON PARKWAY, SUITE 100
BOULDER CO 80301
(City) (State) (Zip)
Director 10% Owner
X Officer (give title below) Other (specify below)
See Remarks
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

  1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price


Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

  1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares


Restricted Stock Units (1) 01/31/2020 A 74,000 (2) (2) Common Stock 74,000 $0.00 74,000 D
Explanation of Responses:

  1. Each Restricted Stock Unit represents the right to receive one share of Common Stock.
  2. The Restricted Stock Units shall vest as to 25% of the units on February 1, 2021, and the remainder shall vest in substantially equal installments over the 12 quarters immediately following such date.
    Remarks:
    Chief Medical Officer and Executive Vice President of Clinical and Preclinical Development and Pharmacovigilance
    /s/ Lindsey Rolfe 01/31/2020
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

  • If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Febreary,21. 2019 CLVS 6 years ago #3563

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
OMB APPROVAL

OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
 Â

  1. Name and Address of Reporting Person*
    Gross Paul Edward

(Last)
(First)
(Middle)
C/O CLOVIS ONCOLOGY, INC.
5500 FLATIRON PARKWAY, SUITE 100

(Street)
BOULDER
CO
80301 2. Issuer Name and Ticker or Trading Symbol
Clovis Oncology, Inc. [ CLVS ] 5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
3. Date of Earliest Transaction (Month/Day/Year)
01/31/2020
4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line)
Gross Paul Edward
(Last) (First) (Middle)
C/O CLOVIS ONCOLOGY, INC.
5500 FLATIRON PARKWAY, SUITE 100
BOULDER CO 80301
(City) (State) (Zip)
Director 10% Owner
X Officer (give title below) Other (specify below)
See Remarks
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

  1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price


Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

  1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares


Restricted Stock Units (1) 01/31/2020 A 74,000 (2) (2) Common Stock 74,000 $0.00 74,000 D
Explanation of Responses:

  1. Each Restricted Stock Unit represents the right to receive one share of Common Stock.
  2. The Restricted Stock Units shall vest as to 25% of the units on February 1, 2021, and the remainder shall vest in substantially equal installments over the 12 quarters immediately following such date.
    Remarks:
    Executive Vice President, General Counsel and Chief Compliance Officer
    /s/ Paul Edward Gross 01/31/2020
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

  • If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Febreary,21. 2019 CLVS 6 years ago #3564

John Midelton!! What do you mean until 2.030. Your price is going to be $8.39. (12/31/2030).

Febreary,21. 2019 CLVS 6 years ago #3565

Summary:

At 4am. Approve France use of rubraca.
At 7am. Take the action 9.00... with little transactions approximately 5k.
On the rest of the day, low volume sales to the Approximately 100 transaction shares to bring it down to $8.39.

Draw your conclusions...

What a negotiation.

The chairman (ceo). Full purchase form (SEC) at the closing price 4: 01 pm to $8.39 per share (procurement 250,000).

They're obviously manipulating the action at their whim.

At some point, it starts the action like a rocket.

We understand your delay.

Cleared the point.

Febreary,21. 2019 CLVS 6 years ago #3566

MAHAFFY PATRICK J (0001266569)
Mailing Address
C/O CLOVIS ONCOLOGY, INC.
5500 FLATIRON PARKWAY, SUITE 100
BOULDER CO 80301
Ownership Reports for Issuers: (Click on issuer name to see other owners for the issuer, or CIK for issuer filings.)

Issuer Filings Transaction Date Type of Owner
Clovis Oncology, Inc. 0001466301 2020-02-03 director, officer: President and CEO
Flexion Therapeutics Inc 0001419600 2019-08-29 director
Orexigen Therapeutics, Inc. 0001382911 2017-07-14 director
PHARMION CORP 0001203866 2008-03-07 director, officer: CEO, President

Items 1 - 80

The information presented below contains only portions of the information presented in the referenced filing or filings.
You should consult the original filing for complete information. Hyperlinks to the forms are provided for your convenience.

Acquistion or Disposition Transaction Date Deemed Execution Date Issuer Form Transaction Type Direct or Indirect Ownership Number of Securities Transacted Number of Securities Owned Line Number Issuer CIK Security Name
A 2020-02-03 Clovis Oncology, Inc. 4 A-Award --D 50000.0000 50000.0000 2 0001466301 Stock Option (right to buy)
A 2020-02-03 Clovis Oncology, Inc. 4 A-Award --D 200000.0000 200000.0000 1 0001466301 Stock Option (right to buy)

Febreary,21. 2019 CLVS 6 years ago #3568

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
 Â
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

  1. Name and Address of Reporting Person*
    MAHAFFY PATRICK J
    (Last) (First) (Middle)
    C/O CLOVIS ONCOLOGY, INC.
    5500 FLATIRON PARKWAY, SUITE 100
    (Street)
    BOULDER CO 80301
    (City) (State) (Zip)
  2. Issuer Name and Ticker or Trading Symbol
    Clovis Oncology, Inc. [ CLVS ] 5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    X Officer (give title below) Other (specify below)
    President and CEO
  3. Date of Earliest Transaction (Month/Day/Year)
    02/03/2020
  4. If Amendment, Date of Original Filed (Month/Day/Year)
  5. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
  6. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
  7. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (right to buy) $8.39 02/03/2020 A 200,000 (1) 02/03/2030 Common Stock 200,000 $0.00 200,000 D
    Stock Option (right to buy) $8.39 02/03/2020 A 50,000 (2) 02/03/2030 Common Stock 50,000 $0.00 50,000 D
    Explanation of Responses:
  8. The option shall vest as to 25% of the shares on January 31, 2021, and the remainder shall vest in substantially equal installments over the 36 months immediately following such date.
  9. The option shall vest upon the submission by the Company to the FDA of an IND for FAP-2286 on or before December 31, 2020.
    Remarks:
    /s/ Patrick J. Mahaffy 02/03/2020
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
  • If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.